Here, we investigated the potential therapeutic effect of inhibiting SOX18 via Sm4 pathway in lymphatic endothelial cells and lymphangiosarcoma cells in vitro to evaluate its role as a treatment target. This evidence concerns the gene SOX18 and lymphangiosarcoma.